UnitedHealth Group has spent the past nine months telling investors its turnaround is ahead of schedule, raising its full-year outlook at every turn. The stock market has stopped listening. Shares have fallen about 17% since the company's last report even as the S&P 500 edged higher, leaving the managed-care giant roughly 20 percentage points behind the broader market. When UnitedHealth reports before the open on October 13, the question is less whether it can clear a modest bar and more whether it can persuade a skeptical market that its improving Medicare story outweighs a commercial business that keeps getting worse.
Wall Street expects adjusted earnings of $4.12 per share, a 41% jump from the $2.92 earned a year ago, on revenue of about $111.4 billion, down 1.6%. That combination tells the story of this recovery: shrinking revenue as the company sheds unprofitable Medicare Advantage members, paired with sharply better margins. The whisper number of $4.60 sits meaningfully above consensus, suggesting the informal bar is higher than published estimates imply. That makes sense given management's guidance. Last quarter it lifted its 2026 adjusted EPS target to $19.50 to $20.00, up from a prior floor of $18.25 and an initial floor of $17.75. The full-year consensus at the time of that raise was $18.39, well short of the new range, so analysts may still be catching up. A third-quarter figure near the whisper would help close that gap; a print near consensus could leave investors wondering whether the second quarter's $6.38 was a high-water mark.